Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|February 1, 2005
Iris pigmentation changes monitored with glaucoma therapy
Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Eyedaptic launches Eva, an agentic AI visual assistant for patients with retinal disease
2
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
3
Eyes on October 2026: AAO and EURETINA highlights, a trio of FDA approvals, and optogenetics takes the spotlight
4
AAO 2026 recap: Christopher J. Rapuano, MD, on the meeting's themes
5